

SRT 1720

Catalog No: tcsc0437



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

925434-55-5

Formula:

$C_{25}H_{23}N_7OS$

Pathway:

Epigenetics; Cell Cycle/DNA Damage

Target:

Sirtuin; Sirtuin

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

469.56

Product Description


SRT 1720 is a selective activator of human **SIRT1** with an **EC_{1.5}** of 0.16 μ M, and shows less potent activities against SIRT2 and

SIRT3 with EC_{1,5}s of 37 μ M and > 300 μ M, respectively.

IC50 & Target: EC1.5: 0.16 μ M (SIRT1), 37 μ M (SIRT2), > 300 μ M (SIRT3)^[1]

In Vitro: SRT 1720 effectively decreases the acetylation of p53 in cells even in the absence of SIRT1, and this is attributed to inhibition of histone acetyltransferase p300^[2].

In Vivo: SRT 1720 (10, 30, 100 mg/kg, p.o.) significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing elevated insulin levels similar to rosiglitazone treatment. SRT 1720 treatment significantly reduces fasting blood glucose to near normal levels in *Lep^{ob/ob}* mice^[1]. SRT 1720 has ability to protect against the negative effects of diet-induced obesity in mice, and has a connection to metabolic adaptation in fatty acid and oxidative metabolism through downstream targets of SIRT1 such as PGC1 α and FOXO1^[2]. SRT 1720 (50-100 mg/kg, p.o.), during emphysema development attenuates elastase-induced airspace enlargement and lung function impairment as well as reduces arterial oxygen saturation in WT mice^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!